MX2010004314A - Compounds for inhibiting ksp kinesin activity. - Google Patents

Compounds for inhibiting ksp kinesin activity.

Info

Publication number
MX2010004314A
MX2010004314A MX2010004314A MX2010004314A MX2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A
Authority
MX
Mexico
Prior art keywords
sup
compounds
ksp kinesin
kinesin activity
inhibiting ksp
Prior art date
Application number
MX2010004314A
Other languages
Spanish (es)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Gerald W Shipps Jr
Xiaohua Huang
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Cliff Cheng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010004314A publication Critical patent/MX2010004314A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

Abstract

The present invention relates to compounds of Formula (I), below, (wherein X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>27</sup>, R<sup>28</sup>, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.
MX2010004314A 2007-11-09 2008-10-16 Compounds for inhibiting ksp kinesin activity. MX2010004314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98679907P 2007-11-09 2007-11-09
PCT/US2008/080176 WO2009061596A1 (en) 2007-11-09 2008-10-16 Compounds for inhibiting ksp kinesin activity

Publications (1)

Publication Number Publication Date
MX2010004314A true MX2010004314A (en) 2010-04-30

Family

ID=40254344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004314A MX2010004314A (en) 2007-11-09 2008-10-16 Compounds for inhibiting ksp kinesin activity.

Country Status (14)

Country Link
EP (1) EP2215064A1 (en)
JP (1) JP2011503076A (en)
KR (1) KR20100075508A (en)
CN (1) CN101952255A (en)
AR (1) AR068889A1 (en)
AU (1) AU2008325025A1 (en)
CA (1) CA2702990A1 (en)
CL (1) CL2008003062A1 (en)
IL (1) IL205181A0 (en)
MX (1) MX2010004314A (en)
PE (1) PE20090968A1 (en)
TW (1) TW200922559A (en)
WO (1) WO2009061596A1 (en)
ZA (1) ZA201002700B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220061B1 (en) * 2007-10-19 2016-02-17 Merck Sharp & Dohme Corp. Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
DE102008001932A1 (en) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiroisoxazolines
EP3119762B9 (en) * 2014-03-20 2021-10-20 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5336470B2 (en) * 1971-08-09 1978-10-03
DE60329990D1 (en) * 2002-03-08 2009-12-24 Merck & Co Inc MITOTIC KINESINE HEMMER
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CA2602146A1 (en) * 2005-04-07 2006-10-19 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
KR20100075508A (en) 2010-07-02
PE20090968A1 (en) 2009-07-13
CN101952255A (en) 2011-01-19
IL205181A0 (en) 2010-11-30
AU2008325025A1 (en) 2009-05-14
CL2008003062A1 (en) 2010-02-19
EP2215064A1 (en) 2010-08-11
TW200922559A (en) 2009-06-01
JP2011503076A (en) 2011-01-27
AR068889A1 (en) 2009-12-16
WO2009061596A1 (en) 2009-05-14
CA2702990A1 (en) 2009-05-14
ZA201002700B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
MX2010004312A (en) Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EP2512479A4 (en) Methods and compositions for treating peripheral vascular disease
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
HK1097189A1 (en) Cannabinoid receptor ligands
IL175714A0 (en) Quinazolinone compounds as anticancer agents
MX2009003157A (en) Therapeutic pyrazolyl thienopyridines.
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
DE602004011394D1 (en) Thiazolderivate
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2012004848A (en) Tricyclic heterocyclic compounds.
MX2010009623A (en) 1-benzyl-3-hydroxymethylindazoiî¹e derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1.
TW200611695A (en) Pyrrolopyridine derivatives
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
MX2009009238A (en) Novel phosphodi esterase inhibitors.
DE602006010738D1 (en) PYRROLOÄ2,3-CÜPYRIDINDERIVATE
MX2009006885A (en) Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal